Hydrocortisone-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•Agonists•ScreeningLibrarieswww.MedChemEHydrocortisoneCat.No.:HY-N0583CASNo.:50-23-7分⼦式:C₂₁H₃₀O₅分⼦量:362.46作⽤靶点:GlucocorticoidReceptor;EndogenousMetabolite作⽤通路:GPCR/GProtein;MetabolicEnzyme/Protease储存⽅式:4°C,protectfromlight*Insolvent:-80°C,6months;-20°C,1month(protectfromlight)溶解性数据体外实验DMSO:≥31mg/mL(85.53mM)扫描⼆维码，H2O:1.2mg/mL(3.31mM;Needultrasonic)运⽤溶解⽅案计算器*"≥"meanssoluble,butsaturationunknown.获得适合您实验体系的溶解⽅案MassSolvent1mg5mg10mgConcentration制备储备液1mM2.7589mL13.7946mL27.5893mL5mM0.5518mL2.7589mL5.5179mL10mM0.2759mL1.3795mL2.7589mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存⽅式和期限。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶1.请依序添加每种溶剂：1%DMSO99%saline2.Solubility:≥0.5mg/mL(1.38mM);Clearsolution请依序添加每种溶剂：10%DMSO40%PEG3005%Tween-8045%salineSolubility:≥2.5mg/mL(6.90mM);Clearsolution此⽅案可获得≥2.5mg/mL(6.90mM，饱和度未知)的澄溶液。1/3www.MedChemEwww.MedChemE以1mL⼯作液为例，取100μL25.0mg/mL的澄DMSO储备液加到400μLPEG300中，混合均匀；向上述3.体系中加⼊50μLTween-80，混合均匀；然后继续加⼊450μL⽣理盐⽔定容⾄1mL。请依序添加每种溶剂：10%DMSO90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(6.90mM);Clearsolution此⽅案可获得≥2.5mg/mL(6.90mM，饱和度未知)的澄溶液。以1mL⼯作液为例，取100μL25.0mg/mL的澄DMSO储备液加到900μL20%的SBE-β-CD⽣理盐⽔⽔溶4.液中，混合均匀。请依序添加每种溶剂：10%DMSO90%cornoilSolubility:≥2.5mg/mL(6.90mM);Clearsolution此⽅案可获得≥2.5mg/mL(6.90mM，饱和度未知)的澄溶液，此⽅案不适⽤于实验周期在半个⽉以上的实验。5.以1mL⼯作液为例，取100μL25.0mg/mL的澄DMSO储备液加到900μL⽟⽶油中，混合均匀。请依序添加每种溶剂：5%DMSO40%PEG3005%Tween-8050%saline6.Solubility:≥2.5mg/mL(6.90mM);Clearsolution请依序添加每种溶剂：5%DMSO95%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(6.90mM);ClearsolutionBIOLOGICALACTIVITY⽣物活性Hydrocortisone(Cortisol)肾上腺⽪质分泌的类醇激素或糖⽪质激素[1]。IC50&TargetHumanEndogenousMetabolite体外研究Hydrocortisone(50nM)showsadose-dependentdown-regulationofGRtranscriptinhCMEC/D3cells.Hydrocortisonesupplementationoftheserum-reducedcelldifferentiationmediumleadstoasignificantincreaseinTERacrossthehCMEC/D3monolayer[1].Hydrocortisone-treatedDendriticcells(DCs)showadecreasedexpressionofMHCIImolecules,thecostimulatorymoleculeCD86,andtheDC-specificmarkerCD83,aswellasastronglyreducedIL-12secretion.Hydrocortisone-treatedDCsinhibitproductionofIFN-γbutinduceanincreasedreleaseofIL-4andnochangeinIL-5[2].Hydrocortisonereducespostischemicoxidativestress,perfusionpressure,andtransudateformation.Hydrocortisoneinhibitspostischemicsheddingofsyndecan-1,heparansulfate,andhyaluronanasisreleaseofhistaminefromresidentmastcells[3].PROTOCOLCellAssay[1]CellsareplatedontopofcollagenIV-coatedtranswellchambersforsix-wellplates(24mmdiameter,membranematerial:polyethyleneterephthalate(PET),0.4μmpores,poredensity1.6×106cm2)atdensitiesof2.5×104cellscm2perwell.Whentheyhavereachedconfluenceatday5,thedifferentexperimentalsetsofcellsaretransferredtodifferentiationmediumcontainingreducedamountsofFCSandtreatedwithTNFαorhydrocortisoneasindicated.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.户使⽤本产品发表的科研⽂献2/3www.MedChemEwww.MedChemE•Nature.2021Jan;589(7843):620-626.•ExpCellRes.2020Aug1;393(1):112054.•CancerManagRes.2019Jun21;11:5557-5572.•FundaçãoOswaldoCruz.InstitutoOswaldoCruz.LaboratóriodeTransmissoresdeHematozoários.2020Sep.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].FörsterC,etal.DifferentialeffectsofhydrocortisoneandTNFalphaontightjunctionproteinsinaninvitromodelofthehumanblood-brainbarrier.JPhysiol.2008Apr1;586(7):1937-49.[2].BellinghausenI,etal.InhibitionofhumanallergicT-cellresponsesbyIL-10-treateddendriticcells:differencesfromhydrocortisone-treateddendriticcells.JAllergyClinImmunol.2001Aug;108(2):242-9.[3].ChappellD,etal.Hydrocortisonepreservesthevascularbarrierbyprotectingtheendothelialglycocalyx.Anesthesiology.2007Nov;107(5):776-84.McePdfHeight关注MCE中国公众号，

获取前沿资讯、最新活动和

实⽤科研⼯具MedChemExpre